The benzodiazepine diazepam demonstrates the usefulness of Syrian hamsters as a model for anxiety testing: Evaluation of other classes of anxiolytics in comparison to diazepam

Behavioural Brain Research

Volumn 218, Issue 1, 2011, Pages 8-14

  Gannon, Robert L ^a   Lungwitz, Elizabeth ^a   Batista, Natalia ^a   Hester, Ian ^a   Huntley, Christina ^a   Peacock, Alyssa ^a   Delagrange, Philippe ^b   Millan, Mark J ^b  

^a VALDOSTA STATE UNIVERSITY   (United States)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antidepressant; Anxiolytic; Biological rhythm; Circadian; Plus maze

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID A RECEPTOR; ANXIOLYTIC AGENT; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CITALOPRAM; DIAZEPAM; FENOBAM; GR 205717; METABOTROPIC RECEPTOR ANTAGONIST; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; UNCLASSIFIED DRUG; VESTIPITANT; VOFOPITANT;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SCREENING; EXPLORATORY BEHAVIOR; MALE; MAZE TEST; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SYRIAN HAMSTER; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CRICETINAE; DIAZEPAM; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; MALE; MESOCRICETUS; MOTOR ACTIVITY;

EID: 78649761520     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.11.029     Document Type: Article

References (41)

1. Alò R., Avolio E., Di Vito A., Carelli A., Facciolo R.M., Canonaco Mi. Distinct α subunit variations of the hypothalamic GABAA receptor triplets (αβγ) are linked to hibernating state in hamsters. BMC Neurosci 2010, 6:11.
2. Atack J.R. Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. Adv Pharmacol 2009, 57:137-185.
3. Brocco M., Dekeyne A., Mannoury la Cour C., Touzard M., Girardon S., Veiga S., et al. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 2008, 18:729-750.
4. Childress S.J., Gluckmann M.I. 1,4-benzodiazepines. J Pharm Sci 1964, 53:577-590.
5. Christmas D., Hood S., Nutt D. Potential novel anxiolytic drugs. Curr Pharm Des 2008, 14:3534-3546.
6. Cloos J.M., Ferreira V. Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 2009, 22:90-95.
7. Da Settimo F., Taliani S., Trincavelli M.L., Montali M., Martini C. GABAA/Bz receptor subtypes as targets for selective drugs. Curr Med Chem 2007, 14:2680-2701.
8. Dekeyne A., Denorme B., Monneyron S., Millan M.J. Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors. Neuropharmacology 2000, 39:1114-1117.
9. Duffy R.A. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs 2004, 9:9-21.
10. Ebner K., Sartori S.B., Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 2009, 15:1647-1674.
11. 1) receptor antagonist, GR 205,171, stereospecifically inhibits light-induced phase advances of hamster circadian activity rhythms. Eur J Pharm 2005, 527:86-93.
12. Gannon R.L., Millan M.J. The corticotropin-releasing factor (CRF)1 receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms. Brain Res 2006, 1083:96-102.
13. Gannon R.L., Millan M.J. Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms. Psychopharmacology 2007, 195:325-332.
14. Gannon RL, Millan MJ. Positive and negative modulation of circadian activity rhythms by mGluR5 and mGluR2/3 metabotropic glutamate receptors. Neuropharmacology; in press. doi:10.1016/j.neuropharm.2010.08.022.
15. 2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: interaction studies with citalopram. Eur Neuropsychopharm 2009, 19:887-897.
16. Griebel G., Moreau J.L., Jenck F., Misslin R., Martin J.R. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 1994, 113:463-470.
17. Herd M.B., Belelli D., Lambert J.J. Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol Ther 2007, 116:20-34.
18. Hodgson R.A., Higgins G.A., Guthrie D.H., Lu S.X., Pond A.J., Mullins D.E., et al. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 2007, 86:431-440.
19. Kehne J.H. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007, 6:163-182.
20. Lewis D.A., Cho R.Y., Carter C.S., Eklund K., Forster S., Kelly M.A., et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 2008, 165:1585-1593.
21. Mayers A.G., Baldwin D.S. Antidepressants and their effect on sleep. Hum Psychopharmacol Clin Exp 2005, 20:533-559.
22. Millan M.J., Brocco M., Gobert A., Dorey G., Casara P., Dekeyne A. Anxiolytic properties of the selective, non-peptidergic CRF1 antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytics agent. Neuropsychopharm 2001, 25:585-600.
23. Moise A.M., Eisenstein S.A., Astarita G., Piomelli D., Hohmann A.G. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology 2008, 200:333-346.
24. Mombereau C., Gur T.L., Onksen J., Blendy J.A. Differential effects of acute and repeated citalopram in mouse models of anxiety and depression. Int J Neuropsychopharmacol 2010, 13:321-334.
25. Morin L.P., Allen C.N. The circadian visual system. Brain Res Rev 2006, 51:1-60.
26. Mrosovsky N., Salmon P.A. Triazolam and phase-shifting acceleration re-evaluated. Chronobiol Int 1990, 7:35-41.
27. Palucha A. Are compounds acting at metabotropic glutamate receptors the answer to treating depression?. Expert Opin Investig Drugs 2006, 15:1545-1553.
28. Partyka A., Kłodzińska A., Szewczyk B., Wierońska J.M., Chojnacka-Wójcik E., Librowski T., et al. Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacol Rep 2007, 59:757-762.
29. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytics role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006, 318:304-311.
30. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
31. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wislowska A., et al. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 2005, 514:25-34.
32. Pollock B.G. Citalopram: a comprehensive review. Expert Opin Pharmacother 2001, 2:681-698.
33. Prendergast B.J., Nelson R.J. Affective responses to changes in day length in Siberian hamsters (Phodopus sungorus). Psychoneuroendocrinology 2005, 30:438-452.
34. Rupniak N.M., Carlson E.J., Webb J.K., Harrison T., Porsolt R.D., Roux S., et al. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytics drugs. Behav Pharmacol 2001, 12:497-508.
35. Sanford A.E., Castillo E., Gannon R.L. Cannabinoids and hamster circadian activity rhythms. Brain Res 2008, 1222:141-148.
36. Wesolowska A., Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 2007, 52:1274-1283.
37. Van Reeth O., Turek F.W. Stimulated activity mediates phase shifts in the hamster circadian clock induced by dark pulses or benzodiazepines. Nature 1989, 339:49-51.
38. Yannielli P.C., Kanterewicz B.I., Cardinali D.P. Daily rhythms in spontaneous and diazepam-induced anxiolysis in Syurian hamsters. Pharm Biochem Behav 1996, 54:651-656.
39. Monteleone P., Maj M. The circadian basis of mood disorders: recent developments and treatment implications. Eur Neuropsychopharm 2008, 18:701-711.
40. Germain A., Kupfer D.J. Circadian rhythm disturbances in depression. Hum Psychopharmacol Clin Exp 2008, 23:571-585.
41. Millan M.J. The neurobiology and control of anxious states. Prog Neurobiol 2003, 70:83-244.